Floatz logo

Olaparib

Refractory Ovarian High Grade Serous Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Refractory Ovarian High Grade Serous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2CCC
Durvalumab
National Cancer Institute (NCI)
Phase 2CCC
Hycamtin
National Cancer Institute (NCI)
Phase 2CCC
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 1CC
IPN 60090
M.D. Anderson Cancer Center
Phase 1CC
Capivasertib
M.D. Anderson Cancer Center
Phase 1CC
Irinotecan
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →